Ovoca Bio PLC Result of EGM (2826P)
February 16 2021 - 8:00AM
UK Regulatory
TIDMOVB
RNS Number : 2826P
Ovoca Bio PLC
16 February 2021
Ovoca Bio plc
("Ovoca" or the "Company")
Result of Extraordinary General Meeting
Dublin, Ireland, 16 February 2021 - Ovoca Bio plc (LSE: OVB;
ISE: OVXA), a biopharmaceutical company with a focus on women's
health, announces that each of the resolutions proposed at the
Extraordinary General Meeting of the Company, held earlier today,
were passed.
The full text of each resolution was included in the Notice of
Extraordinary General Meeting of the Company, circulated to
shareholders on 25 January 2021. The resolutions relate to the
replacement of CREST with Euroclear Bank for electronic settlement
of trading in the ordinary shares of the Company.
Voting on the resolutions was conducted by poll, and the details
of the poll vote are set out below:
% of ISC
Votes for % Votes Against % Votes Total Voted Votes Withheld
Resolution 1:
Shareholders Consent
to Migration 35,370,233 99.99 1,880 0.01 35,372,113 39.99 0
---------- ----- ------------- ---- ----------- -------- --------------
Resolution 2:
Approval and Adoption
of New Articles
of Association
of the Company 35,370,233 99.99 1,880 0.01 35,372,113 39.99 0
---------- ----- ------------- ---- ----------- -------- --------------
Resolution 3:
to give effect
to aspects of
the Migration 35,370,233 99.99 1,880 0.01 35,372,113 39.99 0
---------- ----- ------------- ---- ----------- -------- --------------
Notes
1. Any proxy appointments which gave discretion to the Chair
have been included in the "votes for" total.
2. A "Vote Withheld" is not a valid vote in Irish law and was
not counted in the calculation of the proportion of the votes "For"
or "Against" a resolution.
End
For further information:
Ovoca Bio plc
Kirill Golovanov (Chief Executive)
Tel +353 1 661 9819
info@ovocabio.com
Davy (Nominated Adviser, Euronext Growth Advisor and Broker)
John Frain / Daragh O'Reilly
Tel: +353 1 679 6363
Consilium Strategic Communications
Chris Gardner, Chris Welsh, Carina Jurs
ovocabio@consilium-comms.com
Tel: +44 (0)20 3709 5700
About Ovoca Bio
Ovoca Bio is a European-based biopharmaceutical company with a
focus on women's health. The Company is currently developing a
novel treatment for women with hypoactive sexual desire disorder
(HSDD).
The Company's lead product, BP-101, a novel synthetic peptide
administered through a nasal spray, is clinically validated, with
Phase II and Phase III studies conducted in Russia demonstrating
statistically significant improvement in a number of key efficacy
outcomes, including an increase in female sexual desire and
reduction of symptoms of distress associated with HSDD.
Ovoca Bio is seeking to develop the drug for major global
markets - in particular the United States and Europe, as well as
obtain marketing approval in the Russian Federation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMDZGMZFVDGMZM
(END) Dow Jones Newswires
February 16, 2021 09:00 ET (14:00 GMT)
Ovoca Bio (LSE:OVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ovoca Bio (LSE:OVB)
Historical Stock Chart
From Apr 2023 to Apr 2024
